Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies
Authors: Christoph Schmid, Jürgen Kuball, Gesine Bug
Journal: Journal of Clinical Oncology (2021)

Article Tools REVIEW ARTICLES Immunotherapy for Hematologic Malignancies Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.20.01719 Journal of Clinical Oncology - published online before print January 12, 2021 PMID: 33434060 Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies Christoph Schmid , MD1xChristoph SchmidSearch for articles by this author; Jürgen Kuball , MD2xJürgen KuballSearch for articles by this author; and Gesine Bug , MD3xGesine BugSearch for articles by this author Show More 1Department of Hematology and Oncology, Augsburg University Hospital, Augsburg, Germany2Department of Hematology and Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands3Department of Medicine 2, Goethe University, Frankfurt am Main, Germany https://doi.org/10.1200/JCO.20.01719 First Page Full Text PDF Figures and Tables Supplements © 2021 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: All authorsData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTDefining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic MalignanciesThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Christoph SchmidConsulting or Advisory Role: Roche, Daiichi Sankyo, NovartisSpeakers' Bureau: Jazz PharmaceuticalsExpert Testimony: KiadisTravel, Accommodations, Expenses: Neovii BiotechJürgen KuballEmployment: GadetaStock and Other Ownership Interests: GadetaConsulting or Advisory Role: Gadeta, Novartis (Inst)Speakers' Bureau: Gadeta, Miltenyi BiotechResearch Funding: Gadeta, Miltenyi Biotec, NovartisPatents, Royalties, Other Intellectual Property: Multiple patents on gdTCR sequences isolation strategies and targets in combination with dTCR sequencesTravel, Accommodations, Expenses: Gadeta, Novartis, Miltenyi BiotecGesine BugHonoraria: Jazz Pharmaceuticals, CelgeneConsulting or Advisory Role: Hexal, Novartis, Pfizer, Eurocept, Gilead Sciences, CelgeneResearch Funding: Novartis (Inst)Travel, Accommodations, Expenses: Gilead Sciences, Sanofi, Celgene, Neovii BiotechNo other potential conflicts of interest were reported.